|
Pharmacokinetics of Intermittent Isoniazid Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Pharmacokinetics of Intermittent Isoniazid conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Pharmacokinetics of Intermittent Isoniazid Clinical research trials and Pharmacokinetics of Intermittent Isoniazid medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Pharmacokinetics of Intermittent Isoniazid. Pharmacokinetics of Intermittent Isoniazid Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Pharmacokinetics of Intermittent Isoniazid clinical trial. Test subjects typically obtain the finest healthcare available for their Pharmacokinetics of Intermittent Isoniazid condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pharmacokinetics of Intermittent Isoniazid Pharmacokinetics of Intermittent Isoniazid
Pharmacokinetics of Intermittent Isoniazid
For Condition: Tuberculosis,HIV Infections
Status: No longer recruiting
Sponsor(s): Centers for Disease Control and Prevention , Department of Veterans Affairs
Synopsis: Primary Objectives: 1) To determine the proportion of patients with HIV-related tuberculosis who have abnormal pharmacokinetic parameters for isoniazid and rifabutin. Secondary Objectives: 1) To determine risk factors for abnormal pharmacokinetic parameters for isoniazid and rifabutin. 2) To evaluate the correlation between pharmacokinetic parameters of isoniazid and rifabutin and the occurrence of toxicity attributed to antituberculous therapy. 3) To evaluate the correlation between pharmacokinetic parameters of isoniazid and rifabutin and the efficacy of TB therapy. 4) To define and correlate phenotypic INH acetylator status with the results of genotypic acetylator data obtained in the parent trial.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: - Patients with HIV-related tuberculosis
Total Enrollment:
Location and Contact Information:
Central Arkansas Veterans Health System
Little Rock, Arkansas, 72205
United States
Denver Department of Public Health and Hospitals
Denver, Colorado, 80204
United States
Chicago VA Medical Center (Lakeside)
Chicago, Illinois, 60611
United States
Columbia University/Presbyterian Medical Center
New York City, New York, 10032
United States
University of British Columbia
Vancouver, British Columbia, Canada V5Z 4R4
Canada
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287-0003
United States
LA County/USC Medical Center
Los Angeles, California, 90033
United States
Carolinas Medical Center
Charlotte, North Carolina, 28203
United States
New Jersey Medical School
Newark, New Jersey, 07107-3001
United States
University of Manitoba
Winnipeg, Manitoba, CANADA R3A 1R8
Canada
Hines VA Medical Center
Hines, Illinois, 60141
United States
University of North Texas Health Science Center
Ft. Worth, Texas, 76107-2699
United States
Seattle King County Health Department
Seattle, Washington, 98104
United States
Washington, D.C. VAMC
Washington D.C., District of Columbia, 20422
United States
Duke University Medical Center
Durham, North Carolina, 34222
United States
New York University School of Medicine
New York City, New York, 10016
United States
Harlem Hospital Center
New York City, New York, 10037
United States
Boston Medical Center
Boston, Massachusetts, 02118
United States
Nashville VA Medical Center
Nashville, Tennessee, 37212-2637
United States
Montreal Chest Institute McGill University
Montreal, Quebec, H2X 2P4Pq Canada
Canada
University of California, San Francisco
San Francisco, California, 94110
United States
Thomas Street Clinic
Houston, Texas, 77009
United States
Audi L. Murphy VA Hospital
San Antonio, Texas, 78284
United States
Additional Information:
Study ID Numbers: 2173; 23A
Study Start Date:
Record last reviewed: February 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00023348
Other Tuberculosis Studies:
1. Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users
2. Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
3. Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection
4. Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
5. Tuberculosis Prevention for HIV Infected Adults
Related Studies:
Other Tuberculosis Clinical Trials
Other Manitoba Clinical Trials
Other Winnipeg Clinical Trials
Pharmacokinetics of Intermittent Isoniazid
|
|
|
|
|
|
|
|